What are we looking for in new antipsychotics?

Journal of Clinical Psychiatry

Volumn 72, Issue SUPPL. 1, 2011, Pages 9-13

  Correll, Christoph U ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PHARMACOLOGICAL BIOMARKER; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; ZIPRASIDONE; ZOTEPINE;

ADRENERGIC RECEPTOR BLOCKING; AGGRESSION; AGITATION; AKATHISIA; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; CHOLINERGIC RECEPTOR BLOCKING; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DOPAMINE RECEPTOR BLOCKING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; EXTRAPYRAMIDAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEALTH PROMOTION; HORMONE BLOOD LEVEL; HUMAN; LIFE EXPECTANCY; MAJOR DEPRESSION; METABOLIC DISORDER; NEGATIVE SYNDROME; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REBOUND; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUBSTANCE ABUSE; SUDDEN DEATH; TARDIVE DYSKINESIA; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84555202697     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10075su1.02     Document Type: Review

References (42)

1. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345-357. PubMed
2. Potkin SG. Asenapine: a clinical overview. J Clin Psychiatry. 2011;72(suppl 1):14-18.
3. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(suppl 1):19-23.
4. Kane JM. Lurasidone: a clinical overview. J Clin Psychiatry. 2011;72(suppl 1):24-28.
5. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67(3):231-239. doi:10.101/archgenpsychiatry.2010.10 PubMed
6. Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol. 2001;86(4):376-380. doi:10.1254/jp.86.376 PubMed
7. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21. doi:10.1016/S0924-938(10)71701-6 PubMed
8. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115-1124. doi:10.408/JCP.10r06264yel PubMed
9. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X PubMed
10. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163. doi:10.176/api.ajp.208. 08030368 PubMed
11. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi:10.1093/schbul/sbp16 PubMed
12. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.101/archpsyc.64.6.63 PubMed (Pubitemid 46878665)
13. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161(1):116-124. doi:10.176/api.ajp.161.1.16 PubMed (Pubitemid 38419316)
14. Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375-389. doi:10.1038/np.2010.192 PubMed
15. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121. PubMed
16. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. PubMed
17. Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;(12):CD008141. PubMed
18. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457. doi:10.1093/schbul/sbn018 PubMed
19. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons [published online ahead of print May 31, 2010]. Schizophr Bull. PubMed
20. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425. doi:10.176/api.ajp.161.3.414 PubMed (Pubitemid 38326094)
21. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs [published online ahead of print Oct 18, 2011]. Nat Rev Endocrinol. doi:10.1038/nrendo.201.156. [Epub ahead of print]
22. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. doi:10.1016/j.schres.2010.07.012 PubMed
23. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101 (1-3):273-286. doi:10.1016/j.schres.207.12.487 PubMed
24. Stroup TS, McEvoy JP, Ring KD, et al.; the Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947-956. doi:10.176/api.ajp.201.101609 PubMed
25. Kinon BJ, Stauffer VL, Kollack-Walker S, et al. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 2008;28(6):601-607. doi:10.1097/JCP. 0b013e31818af6c PubMed
26. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004. doi:10.1038/np.2010.78 PubMed
27. Perkins DO. Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences. Adv Stud Med. 2004;4:S982-S986. (Pubitemid 40040865)
28. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006 Apr (http://www.cdc.gov/pcd/ issues/2006/apr/05-0180.htm, accessed August 18, 2011).
29. Correll CU, Druss BG, Lombardo I, et al. Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61(9):892-898. doi:10.176/api.ps.61.9.892 PubMed
30. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235. doi:10.1056/NEJMoa080694 PubMed
31. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891. doi:10.176/api.ps.5.8.86 PubMed (Pubitemid 39025215)
32. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry suppl. 2009;195(52):S29-S36. doi:10.192/bjp.195.52.s29 PubMed
33. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609. PubMed
34. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
35. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095. doi:10.176/api.ajp.163.12.2090 PubMed (Pubitemid 46114228)
36. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. doi:10.1016/S0140-6736(08)60486-9 PubMed (Pubitemid 351418005)
37. Liberman RP, Kopelowicz A, Ventura J, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002; 14(4):256-272. doi:10.1080/0954026021016905 (Pubitemid 35398852)
38. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479. doi:10.176/api.ajp.161.3.473 PubMed (Pubitemid 38326102)
39. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011;36(3):616-626. doi:10.1038/np.2010. 193 PubMed
40. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12(10):934-945. doi:10.1038/sj.mp.4020 PubMed (Pubitemid 47482696)
41. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations and trial design alternatives. Dialogues Clin Neurosci. 2011;13(2):155-172. PubMed
42. Correll CU, Cañas F, Larmo I, et al. Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry. 2011;26(suppl 1):3-16.